A Phase I trial of weekly docetaxel and topotecan for solid tumors

References

• Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–8
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989; 49: 4385–9
   PubMed Web of Science ®Google Scholar
• Burris HA, 3rd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816–20
   PubMed Web of Science ®Google Scholar
• Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991; 193: 27–35
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Cheshire PJ, Hallman JD, 2nd, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393–403
   PubMed Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18: 1062–7
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056–61
   PubMed Web of Science ®Google Scholar
• Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345–52
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14: 503–13
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14: 2785–90
   PubMed Web of Science ®Google Scholar
• McCabe FL, Johnson RK. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest 1994; 12: 308–13
   PubMed Web of Science ®Google Scholar
• Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998; 16: 2233–7
   PubMed Web of Science ®Google Scholar
• Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001; 83: 394–9
   PubMed Web of Science ®Google Scholar
• Fulton B, Spencer CM., Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996; 51: 1075–92
   PubMed Web of Science ®Google Scholar
• Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000; 117(4 Suppl 1): 156S–162S
   Google Scholar
• Hainsworth JD, Burris HA, 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164–8
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA, 3rd, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89: 328–33
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145–57
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212–9
   PubMed Web of Science ®Google Scholar
• Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263–6
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004; 95: 624–31
   PubMed Web of Science ®Google Scholar
• Taron M, Plasencia C, Abad A, Martin C, Guillot M. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs 2000; 18: 139–47
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, et al. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 2000; 18: 3288–94
   PubMed Web of Science ®Google Scholar
• Haddad RI, Van Echo DA. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol 2003; 52: 303–6
   PubMedGoogle Scholar
• Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 2004; 100: 2240–5
   PubMedGoogle Scholar